Kymab Ltd of Cambridge UK has raised an additional $50 million in a Series B financing round bringing the total raised to $90 million. The new funds were provided by Woodford Patient Capital Trust Plc and Malin Corporation Plc, which itself recently raised €330 million in an initial public offering on the Irish Stock Exchange.
Bavarian Nordic A/S reported a 17.9% decline in revenue for the first 2015 quarter to DKK 234.8 million (€31.5 million) and a loss before interest and taxes of DKK 40.2 million compared with a year-earlier profit of DKK 3.4 million.
H. Lundbeck A/S has named Kåre Schultz, a Danish national, as its new president and chief executive officer, effective 20 May. Mr Schultz was most recently president and chief operating officer at Novo Nordisk A/S but left the company following a reorganisation of the executive management team.
GW Pharmaceuticals Plc, a developer of cannabinoid medicines, has raised $179.2 million through a share offering on the Nasdaq exchange, the company’s third follow-on financing following an initial public offering of its shares in the US in May 2013.
MorphosSys AG reported sharply higher first-quarter revenue and earnings following the one-time payment and recognition of deferred income from a since-terminated partnership with Celgene Corp. The partnership was for the development of an antibody targeting CD38 in multiple myeloma.
Affimed Therapeutics AG of Germany is planning a follow-on financing of $35 million on Nasdaq to support development of its portfolio of bispecific antibodies. In September 2014 the company raised $56 million in an initial public offering of its shares.
Labco, a French diagnostics company with 160 laboratories spread over seven countries, is making an initial public offering on its shares on the Euronext Paris stock exchange and a simultaneous secondary offering.
An initial public offering of shares in the Belgium-based molecular diagnostics company, Biocartis Group NV, raised €100 million on Euronext Brussels in late April, making it one of the largest life science offerings on a European stock market this year.
Newron Pharmaceuticals SpA, which has an approved drug for Parkinson’s disease, has raised CHF 24.3 million (€23.6 million) in a private share placement to accelerate the development of its pipeline of candidate treatments for diseases of the central nervous system.
The Clinigen Group Plc, a specialty pharmaceutical company, successfully raised £135 million in late April to finance its £225 million acquisition of Idis Group Holdings Ltd, a supplier of unlicensed medicines to the hospital market.